| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC21560 | RC-3095 Featured | RC-3095 is a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo. RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. RC3095 inhibits tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.R,BRS-1) antagonist. |
|
| DC23935 | CH-5450 | A potent, peptide-inhibitor of human chymase with Ki of 1 nM. |
|
| DC22580 | SCH-1473759 hydrochloride | A potent, picomolar, dual inhibitor of Aurora A and B with IC50 of 0.02 and 0.03 nM, respectively. |
|
| DC22581 | SCH-1473759 | A potent, picomolar, dual inhibitor of Aurora A and B with IC50 of 0.02 and 0.03 nM, respectively. |
|
| DC21334 | MN-25 | A potent, reasonably selective agonist of peripheral cannabinoid receptor with Ki of 11 nM for CB2, 22-fold selectivity over the psychoactive CB1 receptors (Ki=245 nM).. |
|
| DC21377 | NESS-040C5 | A potent, reasonably selective cannabinoid CB2 agonist with Ki of 0.4 nM, 25-fold selectivity over CB1 receptor.. |
|
| DC11958 | CCG 258001 | A potent, relatively selective G protein-coupled receptor kinase GRK2 inhibitor with IC50 of 280 nM. |
|
| DC11957 | CCG 224061 | A potent, relatively selective G protein-coupled receptor kinase GRK2 inhibitor with IC50 of 66 nM. |
|
| DC24036 | DZ-2002 | A potent, reversible type III inhibitor of SAHH (S-adenosyl-L-homocysteine hydrolase) with Ki of 17.9 nM. |
|
| DC22606 | Narlaprevir | A potent, second generation HCV NS3 serine protease inhibitor with Ki of 6 nM. |
|
| DC20766 | BETd-246 | A potent, second-generation BET protein degrader that exhibits superior selectivity, potency and antitumor activity. |
|
| DC20583 | WNK inhibitor 7 | A potent, selectiive inhibitor of WNK1 kinase with IC50 of 95 nM, shows IC50 of 1.39 uM in the cellular OSR1 phosphorylation assay with reasonable aqueous solubility.. |
|
| DC21271 | Volinanserin (MDL100907) Featured | A potent, selective 5-HT2A receptor antagonist with Ki of 0.36 nM, > 80-fold selectivity for 5-HT2A over other serotonergic receptors. |
|
| DC20851 | BW-723C86 Featured | A potent, selective 5-HT2B receptor agonist with pKi of 7.1, >10-fold selectivity over 5-HT2A, 5-HT2C, and other 5-HT subtypes. |
|
| DC21285 | MK-212 | A potent, selective 5-HT2C receptor agonist with IC50 of 20 nM in HEK293 cells-exppressed 5-HT2C, shows weakly activity for 5-HT2A. |
|
| DC22915 | ST-1535 | A potent, selective A2A adenosine receptor antagonist with Ki of 6.6 nM. |
|
| DC23941 | RU-24969 Featured | A potent, selective agonist of 5-HT1A and 5-HT1B receptors, with preference for 5-HT1B. |
|
| DC23002 | DAA-1097 | A potent, selective agonist of PBR/TSPO that inhibits [3H]PK 11195 binding to crude mitochondrial preparations of rat whole brain with IC50 of 0.92 nM.. |
|
| DC22698 | CE-326597 | A potent, selective agonist of the human and rat CCK1 receptor with Ki of 36 nM. |
|
| DC20295 | 2-PCCA | A potent, selective agonist of the orphan GPR88 receptor with EC50 of 877 nM. |
|
| DC24029 | PF-4840154 | A potent, selective agonist of the rat (EC50=97 nM) and human (EC50=23 nM) TRPA1 channel. |
|
| DC23831 | TASP0382088 | A potent, selective ALK5 inhibitor with IC50 of 4.8 nM, >100-fold selectivity over 95 different kinases. |
|
| DC20564 | TBBz Featured | A potent, selective and ATP-competitive CK2 inhibitor with Ki of 0.5-1 uM. |
|
| DC20686 | AS602868 | A potent, selective and ATP-competitive inhibitor of IKK2 with IC50 of 60 nM and Ki of 20 nM, also interfers directly with FLT3 kinase activation. |
|
| DC22817 | RUSKI-201 | A potent, selective and cell active Hedgehog acyltransferase (Hhat) inhibitor with IC50 of 0.87 uM. |
|
| DC22867 | HR22C16 | A potent, selective and cell permeable inhibitor of mitotic kinesin Eg5 with IC50 of 0.8 uM, does not interact with other microtubule motor proteins. |
|
| DC20309 | ANTISAUVAGINE-30 Featured | A potent, selective and competitive corticotropin-releasing factor CRF2 receptor antagonist with Ki of 1.4 nM, 100-fold selectiivity over CRF1. |
|
| DC22763 | Rilapladib | A potent, selective and oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.23 nM, for the treatment of Alzheimer's disease and atherosclerosis.. |
|
| DC21210 | Rolofylline | A potent, selective and orally active adenosine A1 receptor antagonist with Ki of 1.3 nM. |
|
| DC21827 | XE 991 dihydrochloride Featured | A potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively. |
|
